Myelodysplastic syndrome

Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?


Indications of allogeneic hematopoietic stem cell transplantation (HSCT) remain controversial in patients with lower risk myelodysplastic syndrome. We review prognostic factors in lower risk MDS, delineating patients with relatively poor risk who may potentially benefit from HSCT during the disease course. Results of HSCT in those patients, and main efforts to decrease non-relapse mortality (NRM) are detailed. Prospective studies are needed to determine more precisely which lower risk MDS patients may benefit from transplantation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Estimation of NRM according to disease risk, comorbidity score, type of donor, and conditioning regimen (published by Carre et al [33]).


  1. 1.

    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  PubMed  Google Scholar 

  2. 2.

    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

    CAS  PubMed  Google Scholar 

  3. 3.

    Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496–501.

    CAS  PubMed  Google Scholar 

  5. 5.

    Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.

    CAS  PubMed  Google Scholar 

  6. 6.

    Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–70.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transpl. 2012;18:1415–21.

    Google Scholar 

  8. 8.

    Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131:818–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia. 2019;33:686–95.

    PubMed  Google Scholar 

  10. 10.

    Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017;31:2449–57.

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017;31:1391–7.

    CAS  PubMed  Google Scholar 

  12. 12.

    Ramos F, Robledo C, Izquierdo-García FM, Suárez-Vilela D, Benito R, Fuertes M, et al. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. Oncotarget. 2016;7:30492–503.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, et al. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. Blood Adv. 2018;2:2079–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27. quiz 3699.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49:204–12.

    CAS  PubMed  Google Scholar 

  16. 16.

    Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129:2347–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–7.

    PubMed  Google Scholar 

  18. 18.

    Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl J Med. 2011;364:2496–506.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30:3376–82.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl J Med. 2018;378:2386–98.

    CAS  PubMed  Google Scholar 

  22. 22.

    Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Walter-petrich A, Lehmann che J, et al. APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the groupe francophone des myélodysplasies (GFM). Blood. 2019;134:677–677.

    Google Scholar 

  23. 23.

    Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574–82.

    CAS  PubMed  Google Scholar 

  24. 24.

    List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl J Med. 2006;355:1456–65.

    CAS  PubMed  Google Scholar 

  25. 25.

    Park S, Hamel J-F, Toma A, Kelaidi C, Thépot S, Campelo MD, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol J Am Soc Clin Oncol. 2017;35:1591–7.

    Google Scholar 

  26. 26.

    Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: a retrospective multinational study. Int J Mol Sci. 2017;18.

  27. 27.

    Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N. Engl J Med. 2020;382:140–51.

    CAS  PubMed  Google Scholar 

  28. 28.

    Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27:1283–90.

    CAS  PubMed  Google Scholar 

  30. 30.

    Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, et al. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017;8:81926–35.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    Baek DW, Lee YJ, Kim H, Ahn SY, Ahn JS, Shin HJ, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Ann Hematol. 2018;97:2309–17.

    CAS  PubMed  Google Scholar 

  32. 32.

    Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015;121:876–82.

    PubMed  Google Scholar 

  33. 33.

    Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, et al. Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019.

  34. 34.

    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transpl. 2017;52:209–15.

    CAS  Google Scholar 

  35. 35.

    Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl J Med. 2017;377:2433–44.

    CAS  PubMed  Google Scholar 

  36. 36.

    Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333–42.

    PubMed  Google Scholar 

  37. 37.

    Shaffer BC, Ahn KW, Hu Z-H, Nishihori T, Malone AK, Valcárcel D, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol J Am Soc Clin Oncol. 2016;34:1864–71.

    Google Scholar 

  38. 38.

    Gagelmann N, Eikema D-J, Stelljes M, Beelen D, de Wreede L, Mufti G, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019;104:929–36.

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2016.

  41. 41.

    de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420–31.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial. Biol Blood Marrow Transpl. 2016;22:385–90.

    CAS  Google Scholar 

  43. 43.

    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transpl. 2015;21:1761–9.

    CAS  Google Scholar 

  44. 44.

    Oshikawa G, Kakihana K, Saito M, Aoki J, Najima Y, Kobayashi T, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015;169:756–9.

    CAS  PubMed  Google Scholar 

  45. 45.

    Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, et al. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transpl. 2019;54:1815–26.

    CAS  Google Scholar 

  46. 46.

    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, et al. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transpl. 2019;54:839–48.

    CAS  Google Scholar 

  48. 48.

    Yang Y, Tang Z, An T, Zhao L. The impact of iron chelation therapy on patients with lower/intermediate IPSS MDS and the prognostic role of elevated serum ferritin in patients with MDS and AML: A meta-analysis. Med (Baltim). 2019;98:e17406.

    CAS  Google Scholar 

  49. 49.

    Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32:29–35.

    CAS  PubMed  Google Scholar 

  50. 50.

    Hilken A, Langebrake C, Wolschke C, Kersten JF, Rohde H, Nielsen P, et al. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). Ann Hematol. 2017;96:1379–88.

    CAS  PubMed  Google Scholar 

  51. 51.

    Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018;5:e201–10.

    PubMed  Google Scholar 

  52. 52.

    Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179:83–97.

    CAS  PubMed  Google Scholar 

  53. 53.

    Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172:513–22.

    PubMed  Google Scholar 

  54. 54.

    Cremers EMP, de Witte T, de Wreede L, Eikema D-J, Koster L, van Biezen A, et al. A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:2404–14.

    CAS  PubMed  Google Scholar 

  55. 55.

    Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119:3908–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transpl. 2014;20:1975–81.

    Google Scholar 

  57. 57.

    Wang Y, Wang H-X, Lai Y-R, Sun Z-M, Wu D-P, Jiang M, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016.

  58. 58.

    Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, et al. HLA-mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transpl. 2019;25:114–20.

    Google Scholar 

  59. 59.

    Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017;1:1876–83.

    PubMed  PubMed Central  Google Scholar 

  60. 60.

    Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, et al. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transpl. 2018;53:756–63.

    CAS  Google Scholar 

  61. 61.

    Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, et al. Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020.

  62. 62.

    Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, et al. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from eurocord (cord blood committee of cellular therapy & immunobiology working party of EBMT) and chronic malignancies working party. Biol Blood Marrow Transpl. 2014;21:489–95.

    Google Scholar 

  63. 63.

    Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46.

    CAS  PubMed  Google Scholar 

  64. 64.

    Kröger N, Iacobelli S, Franke G-N, Platzbecker U, Uddin R, Hübel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol J Am Soc Clin Oncol. 2017;35:2157–64.

    Google Scholar 

  65. 65.

    Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol J Am Soc Clin Oncol. 2017;35:1154–61.

    Google Scholar 

  66. 66.

    Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2019.

Download references

Author information



Corresponding author

Correspondence to Marie Robin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Robin, M., Fenaux, P. Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. Leukemia (2020).

Download citation